ストックスクリーナーアプリを入手
0.6971
7.93%
0.0512
アフターアワーズ：
.67
-0.0271
-3.89%
前日終値:
$0.6459
開ける：
$0.6227
24時間の取引高:
7.45M
Relative Volume:
3.52
時価総額：
$13.33M
収益：
-
当期純損益:
$-12.47M
株価収益率:
-0.7651
EPS:
-0.9111
ネットキャッシュフロー:
$-10.10M
1週間 パフォーマンス:
+23.97%
1か月 パフォーマンス:
-32.32%
6か月 パフォーマンス:
-54.44%
1年 パフォーマンス:
-13.55%
1日の値動き範囲:
$0.583
$0.722
1週間の範囲:
$0.4894
$0.7816
52週間の値動き範囲:
$0.4894
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
名前
Hoth Therapeutics Inc
セクター
電話
(646)756-2997
住所
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.6971 | 12.35M | 0 | -12.47M | -10.10M | -0.9111 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-10-15 | 開始されました | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc (HOTH) 最新ニュース
Hoth Therapeutics Reports Positive HT VA Study Data Highlighting GDNF Driven Metabolic Reprogramming In Fatty Liver Disease - BioPharma APAC
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Emerging Now: ANY, GPRO, HOTH, SNAL Shift Strategic Focus in 2026 - Barchart
12 Health Care Stocks Moving In Tuesday's Intraday SessionAdagio Medical Holdings (NASDAQ:ADGM), Allog - Benzinga
Move Over Novo NordiskThis Small Company Study Flags Edge In Fatty Liver Drug - Benzinga
Why is HOTH stock up 70% after-hours today? - MSN
Positive Results for Hoth Therapeutics (HOTH) in Liver Disease S - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide - Yahoo Finance
Trending Stocks Today | Perfect Moment Surges 88.88% Pre-Market - Moomoo
Hoth Therapeutics Reports Positive GDNF Data for Fatty Liver Disease - National Today
Why Is HOTH Stock Up 70% After-Hours Today? - Stocktwits
Hoth Therapeutics (Hoth) Reports Positive Ht-Va Crada Data Gdnf Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene And Activates Fat-Burning Pathways, Outperforming Semaglutide - TradingView — Track All Markets
Hoth Therapeutics announces issuance of Chinese patent for cancer cell-targeting technology - SelectScience
HOTH.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aug Update: Is Hoth Therapeutics Inc benefiting from innovation trends2026 Decliners & High Accuracy Investment Entry Signals - baoquankhu1.vn
HOTH.O Technical Analysis & Stock Price Forecast - Intellectia AI
Trend Report: Is Hoth Therapeutics Inc stock trending bullish2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
HOTH.O PE Ratio & Valuation, Is HOTH.O Overvalued - Intellectia AI
HOTH.O Forecast — Price Prediction for 2026. Should I Buy HOTH.O? - Intellectia AI
Exclusive: Hoth Therapeutics targets faster drug discovery with new AI platform - MSN
HOTH.O - Reuters
Guidance Update: Whats the fair value of Hoth Therapeutics Inc stock2026 Earnings Surprises & Stock Timing and Entry Methods - baoquankhu1.vn
Hoth Therapeutics Completes Registered Direct Offering Financing - The Globe and Mail
Hoth Therapeutics, Inc. (HOTH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Hoth Therapeutics, Inc. (HOTH) stock price, news, quote and history - Yahoo Finance UK
Hoth Therapeutics closes $2 million registered direct offering By Investing.com - Investing.com Canada
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering - Lelezard
Hoth Therapeutics announces closing of $2 million registered direct offering - marketscreener.com
Hoth Therapeutics Announces Closing Of $2 Million Registered Direct Offering - TradingView
Hoth Therapeutics Raises $2M in Registered Direct Offering - National Today
Hoth Therapeutics closes $2 million registered direct offering - Investing.com
Hoth Therapeutics Raises $2 Million in Registered Direct Offering; Issues Five-Year Warrants - TradingView — Track All Markets
Hoth Therapeutics (NASDAQ: HOTH) closes $2M registered direct stock deal - Stock Titan
Hoth Therapeutics (NASDAQ: HOTH) raises ~$2.0M; concurrent warrants issued - Stock Titan
Hoth Therapeutics’ HT-001 meets primary endpoint in interim analysis By Investing.com - Investing.com South Africa
Hoth Therapeutics raises $2M in registered direct offering By Investing.com - Investing.com Australia
Hoth Therapeutics raises $2M in registered direct offering - Investing.com
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering - PR Newswire
Hoth Therapeutics’ HT-001 meets primary endpoint in interim analysis - Investing.com
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six - PR Newswire
Hoth Therapeutics receives China patent for mast cell therapy By Investing.com - Investing.com Australia
Energy Moves: Is Hoth Therapeutics Inc stock trending bullish2026 Dividend Review & AI Enhanced Trading Signals - baoquankhu1.vn
Hoth Therapeutics receives China patent for mast cell therapy - Investing.com
Hoth Therapeutics Announces Issuance Of Chinese Patent For Cancer Cell-Targeting Technology - TradingView
China patent backs Hoth technology designed to kill mast cells - Stock Titan
Moving Averages: Is Hoth Therapeutics Inc a good ESG investment2026 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Hoth Therapeutics 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, FDA Regulatory Pathways, and Risk Factors Overview - Minichart
Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Hoth Therapeutics 10-K: $0 Revenue, $(0.90) EPS, $(12.47)M Net Loss - tradingview.com
Hoth Therapeutics (NASDAQ: HOTH) warns on cash needs and going‑concern risk - Stock Titan
Hoth Therapeutics Inc (HOTH) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):